Catalyst Pharmaceuticals Inc (STU:CN2)
€ 20.71 0.15 (0.73%) Market Cap: 2.46 Bil Enterprise Value: 2.04 Bil PE Ratio: 18.19 PB Ratio: 3.87 GF Score: 88/100

Q3 2024 Catalyst Pharmaceuticals Inc Earnings Call Transcript

Nov 07, 2024 / 01:30PM GMT
Release Date Price: €21.71 (+2.60%)
Operator

Thank you for standing by. My name is Chris and I will be your conference operator today. At this time, I would like to welcome everyone to the Catalyst Pharmaceuticals third quarter, 2024 financial results conference call lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question. Press star one again. Thank you. I would now like to turn the call over to my CFO. Please go ahead.

Michael Kalb
Catalyst Pharmaceuticals Inc - Chief Financial Officer

Thank you. Good morning everyone and thank you for joining our conference call to discuss Catalyst Pharmaceuticals third quarter, 2024 financial results and business highlights Rich Daly President and CEO will lead the call today. And Jeff Del Carmen, our Chief Commercial Officer and I will also present additionally, Dr Steve Miller, our Chief Operating Officer and Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot